International Journal of Hyperthermia

International Journal of Hyperthermia

Published by Taylor & Francis

Online ISSN: 1464-5157

·

Print ISSN: 0265-6736

Journal websiteAuthor guidelines

Top read articles

226 reads in the past 30 days

MRI sagittal view of a patient with uterine fibroid. (a) the distance from ventral surface of the fibroid to skin, (b) the distance from dorsal surface of the fibroid to sacrum, (c) thickness of abdominal wall.
The location of the endopelvic fascial edema. (a-d) MR images before USgHIFU ablation. (e) Anterior wall fascial edema; (f) posterior wall fascial, right lateral wall fascial, peri-vesical fascial, and perirectal fascial edema; (g) posterior wall fascial, left lateral wall fascial edema; (h) peri-uterine fascial, posterior wall fascial, and perirectal fascial edema.
A 44 years old patient with fibroid. (a-d) MRI images before USgHIFU ablation. (e-h) MRI images after USgHIFU ablation. (a) Pre-USgHIFU a sagittal T2WI image showed a posterior wall fibroid that is almost hyperintense on T2WI. (e-f) Fascial edema was shown as a high-intensity signal on T2WI and diffusion-weighted imaging (arrow).
Violin plot analysis of each quantitative parameter between the edema and non-edema groups (a–i). White dash lines represent median values. TD: therapeutic dose; EEF: energy efficiency factor
Univariate analysis to evaluate the relationship between the endopelvic fascial edema and ultrasound ablation parameters.

+3

Factors influencing magnetic resonance imaging finding of endopelvic fascial edema after ultrasound-guided high-intensity focused ultrasound ablation of uterine fibroids

August 2022

·

424 Reads

·

2 Citations

Yuhang Liu

·

Yang Liu

·

Fajin Lv

·

[...]

·

Furong Lv
Download

Aims and scope


Publishes articles on various aspects of thermal energy and thermal therapy in clinical, biological or engineering studies involving human or animals.

  • The International Journal of Hyperthermia publishes peer reviewed research and clinical studies on thermal energy-based disease treatments.
  • It is the official journal of the Society for Thermal Medicine, the European Society for Hyperthermic Oncology, and the Japanese Society for Thermal Medicine.
  • The journal publishes research, perspectives, and letters related to the clinical studies, biological studies, and physics/engineering studies of therapeutic thermal therapies.
  • The journal covers the following topics: Clinical studies describing whole, regional or local treatment in humans or other animals covering the application of therapeutic thermal energy treatment alone or in combination with other clinical modalities, Clinical outcomes on the physiological effects of heat or cold stress, Clinical testing of methods related to thermal technologies, Biological studies incorporating biochemical, anatomical or physiological studies and …

For a full list of the subject areas this journal covers, please visit the journal website.

Recent articles


Frequency of macroscopic suspicion of omental metastases and omentectomy in patients with pseudomyxoma peritonei (PMP) or colorectal peritoneal metastases (PM) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
aFor five patients, the surgeon was uncertain, and for three patients, information was missing.
bFor five patients, the surgeon was uncertain, and for one patient, information was missing.
Cross-tabulation Of macroscopic suspicion of omental metastases (OM) versus microscopically confirmed OM in patients with pseudomyxoma peritonei (PMP) who underwent omentectomy.
aFor eight patients, information on macroscopy or microscopy was lacking, and these patients were not included in the cross-tabulation.
Cross-tabulation Of macroscopic suspicion of omental metastases (OM) versus microscopically confirmed OM in patients with colorectal peritoneal metastases (PM) who underwent omentectomy.
aFor ten patients, information on macroscopy or microscopy was lacking, and these patients were not included in the cross-tabulation.
a. Overall survival for patients with pseudomyxoma peritonei with or without omental metastases (OM + vs. OM-). b. Overall survival for patients with colorectal peritoneal metastases and OM + or OM.
Omental metastases in patients with pseudomyxoma peritonei or colorectal peritoneal metastases – is routine omentectomy justified?
  • Article
  • Full-text available

June 2024

Malin Enblad

·

Helgi Birgisson

·

Lana Ghanipour

·

[...]

·

Wilhelm Graf

Background The greater omentum is routinely resected during cytoreductive surgery (CRS), but few studies have analyzed the rationale behind this. This study aimed to assess the prevalence of omental metastases (OM) and the correlation between macroscopically suspected and microscopically confirmed OM, in patients with pseudomyxoma peritonei (PMP) or colorectal peritoneal metastases (PM). Method All patients without previous omentectomy, treated with initial CRS and hyperthermic intraperitoneal chemotherapy for PMP or colorectal PM, at Uppsala University Hospital in 2013–2021, were included. Macroscopic OM in surgical reports was compared with histopathological analyses. Results In all, 276 patients were included. In those with PMP, 112 (98%) underwent omentectomy and 67 (59%) had macroscopic suspicion of OM. In 5 (4%) patients, the surgeon was uncertain. Histopathology confirmed OM in 81 (72%). In patients with macroscopic suspicion, 96% had confirmed OM (positive predictive value, PPV). In patients with no suspicion, 24% had occult OM (negative predictive value, NPV = 76%). In patients with colorectal PM, 156 (96%) underwent omentectomy and 97 (60%) had macroscopic suspicion. For 5 (3%) patients, the surgeon was uncertain. OM was microscopically confirmed in 90 (58%). PPV was 85% and NPV was 89%. The presence of OM was a univariate risk factor for death in PMP (HR 3.62, 95%CI 1.08–12.1) and colorectal PM (HR 1.67, 95%CI 1.07–2.60), but not in multivariate analyses. Conclusion OM was common and there was a high risk of missing occult OM in both PMP and colorectal PM. These results support the practice of routine omentectomy during CRS.

Share

Mild heat stress (MHS) affects cell viability and YAP activity. (a) Schematic representation of the heating apparatus. MDPC-23 cells were heated using block heaters within a cell incubator, while a thermocouple monitored the temperature of the cell medium. (b) Real-time temperature recording in the cell culture medium via a thermocouple. Approximately 15 min were required to reach an equilibrium temperature, sustaining stability thereafter. (c) The cell area of MDPC-23 cells under MHS. (d) The viability of MDPC-23 cells under MHS. (e) The gene expression of HSP70 under MHS. (f) The gene expression of HSP90α under MHS. (g) Representative images of immunostained YAP under dynamic MHS. Scale bar, 10 μm. (h) Representative images of immunostained YAP under mixed MHS. Scale bar, 10 μm. (i) Quantification of the nucleo-cytoplasmic ratio in (g). (j) The relative protein levels of pYAP and YAP in MDPC-23 cells under dynamic MHS determined by Western blotting. (k) Quantification of the nucleo-cytoplasmic ratio in (h). (l) The relative protein levels of pYAP and YAP in MDPC-23 cells under mixed MHS determined by Western blotting. (Mean ± SD. ns, no statistically significant difference; *p < 0.05; **p < 0.01; ****p < 0.0001).
YAP is crucial for the maintenance of cell viability under mild heat stress (MHS). (a) Representative images of immunofluorescence-stained YAP in MDPC-23 cells pretreated with verteporfin under dynamic MHS. Scale bar, 10 μm. (b) Representative images of immunostained YAP in MDPC-23 cells pretreated with verteporfin under mixed MHS. Scale bar, 10 μm. (c) Quantification of the immunofluorescence staining and nucleo-cytoplasmic ratio in (a). (d) Quantification of the immunofluorescence staining and nucleo-cytoplasmic ratio in (b). (e) The relative protein levels of YAP in MDPC-23 cells pretreated with verteporfin under dynamic MHS. (f) The relative protein levels of YAP in MDPC-23 cells pretreated with verteporfin under mixed MHS. (g) The viability of MDPC-23 cells pretreated with verteporfin under MHS. (h) The gene expression of HSP90α in MDPC-23 cells treated with verteporfin under MHS. (Mean ± SD. ns, no statistically significant difference; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Mild heat stress (MHS) promotes odontoblast differentiation of MDPC-23 cells. (a) Representative images of immunofluorescence-stained DSPP under dynamic MHS. Scale bar, 50 μm. (b) Representative images of immunofluorescence-stained DSPP under mixed MHS. Scale bar, 50 μm. (c) Quantification of the immunofluorescence staining in (a). (d) The relative protein levels of DSPP in MDPC-23 cells under dynamic MHS. (e) Quantification of the immunofluorescence staining in (b). (f) The relative protein levels of DSPP in MDPC-23 cells under mixed MHS. (g) The gene expression of DMP1 in MDPC-23 cells under MHS. (h) The gene expression of HSP25 in MDPC-23 cells under MHS. (Mean ± SD. ns, no statistically significant difference; *p < 0.05; ****p < 0.0001).
YAP is crucial for the odontoblast differentiation of MDPC-23 cells under mild heat stress (MHS). (a) Representative images of immunofluorescence-stained DSPP in MDPC-23 cells pretreated with verteporfin under dynamic MHS. Scale bar, 30 μm. (b) Representative images of immunofluorescence-stained DSPP in MDPC-23 cells pretreated with verteporfin under mixed MHS. Scale bar, 30 μm. (c) Quantification of the fluorescence intensities in (a). (d) The relative protein levels of DSPP in MDPC-23 cells pretreated with verteporfin under dynamic MHS. (e) Quantification of the immunofluorescence staining in (b). (f) The relative protein levels of DSPP in MDPC-23 cells pretreated with verteporfin under mixed MHS. (g) The gene expression of DMP1 in MDPC-23 cells pretreated with verteporfin under MHS. (h) The gene expression of HSP25 in MDPC-23 cells pretreated with verteporfin under MHS. (Mean ± SD. ns, no statistically significant difference; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Proposed model for the regulation of cell viability and odontoblast differentiation in MDPC-23 cells via YAP under mild heat stress (MHS). We propose that MHS enhances YAP activation, thereby maintaining cell viability and promoting odontoblast differentiation in MDPC-23 cells. Heat shock proteins collaborate to maintain cellular homeostasis, and interact with YAP.
Mild heat stress promotes the differentiation of odontoblast-like MDPC-23 cells via yes-associated protein

June 2024

·

2 Reads

Purpose Dentin hypersensitivity (DH) is a prevalent condition, but long-term effective treatments are scarce. Differentiation of odontoblast-like cells is promising for inducing tertiary dentinogenesis and ensuring sustained therapeutic efficacy against DH. This study examined the effects and mechanism of action of mild heat stress (MHS) on the differentiation of odontoblast-like MDPC-23 cells. Methods We used a heating device to accurately control the temperature and duration, mimicking the thermal microenvironment of odontoblast-like cells. Using this device, the effects of MHS on cell viability and differentiation were examined. Cell viability was assessed using the MTT assay. The expression and nucleoplasmic ratio of the yes-associated protein (YAP) were examined by western blotting and immunofluorescence. The gene expression levels of heat shock proteins (HSPs) and dentin matrix protein-1 (DMP1) were measured using qPCR. Dentin sialophosphoprotein (DSPP) expression was evaluated using immunofluorescence and immunoblotting. Verteporfin was used to inhibit YAP activity. Results Mild heat stress (MHS) enhanced the odontoblast differentiation of MDPC-23 cells while maintaining cell viability. MHS also increased YAP activity, as well as the levels of HSP25 mRNA, HSP70 mRNA, HSP90α mRNA, DMP1 mRNA, and DSPP protein. However, after YAP inhibition, both cell viability and the levels of HSP90α mRNA, DMP1 mRNA, and DSPP protein were reduced. Conclusion YAP plays a crucial role in maintaining cell viability and promoting odontoblast differentiation of MDPC-23 cells under MHS. Consequently, MHS is a potential therapeutic strategy for DH, and boosting YAP activity could be beneficial for maintaining cell viability and promoting odontoblast differentiation.


MWA combined with TGF-β1 inhibitor decreases survival rate of HCC cells. (A) Chemical structure of SB-525334. (B) Schematic illustration of MWA combined with TGF-β1 inhibitor (SB-525334). (C) Time temperature curve under 15 W MWA. (D) The IC50 value of SB-525334 was measured in HepG2 and Huh7 cells via MTT assays. (E) MTT assays to detect the role of MWA combined with SB-525334 in cell survival at different temperatures. Data were analyzed by one way analysis of variance followed by Tukey’s post hoc analysis and Student’s t test and expressed as mean ± SD of three independent experiments. *p < .05, **p < .01, ***p < .001 vs. NS (37 °C) group.
MWA combined with TGF-β1 inhibitor promotes the apoptosis of HCC cells. (A) CCK-8 assays to evaluate cell viability in the control (37 °C) + NS, the control (37 °C) + SB, the MWA (50 °C) + NS and the MWA (50 °C) + SB groups. (B–C) The apoptosis of HepG2 and Huh7 cells was assessed via flow cytometry. (D–E) Western blotting to measure the protein levels of cleaved caspase-3, caspase-9 and PARP in HepG2 and Huh7 cells. Data were analyzed by one-way analysis of variance followed by Tukey’s post hoc analysis and expressed as mean ± SD of three independent experiments. *p < .05, **p < .01, ***p < .01.
TGF-β1 inhibitor effectively inactivates the TGF-β1/Smad2/Smad3 pathway in HCC cells. (A–B) Western blotting to assess the protein levels of TGF-β1, phosphorylated Smad2, and phosphorylated Smad3 in HepG2 and Huh7 cells. Data were analyzed by one way analysis of variance followed by Tukey’s post hoc analysis and expressed as mean ± SD of three independent experiments. *p < .05, **p < .01, ***p < .001.
MWA combined with TGF-β1 inhibitor inhibits tumor growth and histopathological changes in vivo. (A) The gross manifestation of tumors on day 22 after MWA. (B) Changes in tumor volume were recorded at the indicated time points. (C) Immunohistochemistry staining was used to detect the expression of Ki67. (D) Histopathological changes of tumor tissues were examined by hematoxylin and eosin staining, and quantification of tumor infiltration area, blood vessel density, cells with nuclear collapse and cells with condensed chromatin was conducted. Black and red arrows represent blood vessels and tumor infiltration, respectively. Blue arrow represents nuclear deformation and chromatin condensation. (E) TUNEL staining was performed to assess tumor apoptosis. Data were analyzed by one way analysis of variance followed by Tukey’s post hoc analysis and expressed as mean ± SD of three independent experiments. N = 5 mice each group. *p < .05, **p < .01, ***p < .001.
MWA combined with TGF-β1 inhibitor promotes the apoptosis of tumor cells by inactivating the TGF-β1/Smad2/Smad3 in vivo. (A–B) Western blotting to measure the protein levels of cleaved caspase-3, cleaved caspase-9 and cleaved PARP. (C–D) Western blotting to measure the protein levels of TGF-β1, phosphorylated Smad2 and phosphorylated Smad3. Data were analyzed by one-way analysis of variance followed by Tukey’s post hoc analysis and expressed as mean ± SD of three independent experiments. N = 3 mice each group. *p < .05, **p <.01, ***p < .001.
TGF-β1 inhibitor enhances the therapeutic effect of microwave ablation on hepatocellular carcinoma

Background Microwave ablation (MWA) is a widely adopted treatment technique for hepatocellular carcinoma (HCC). However, MWA alone is of limited use and has a high recurrence rate. Transforming growth factor-β1 (TGF-β1) is recognized as a potential therapeutic target for HCC patients. Therefore, this study was designed to investigate whether the TGF-β1 inhibitor could increase the efficacy of MWA therapy for HCC treatment. Methods In vitro, HCC cells challenged with TGF-β1 inhibitor (SB-525334), or normal saline were then heated by microwave. Methyl tetrazolium assays were performed to detect cell survival rate and half-maximal drug inhibitory concentration (IC50). Cell viability and apoptosis were detected by cell counting kit-8 assays, flow cytometry and western blotting. In vivo, the mice injected with HepG2 cells received oral gavage of SB-525334 (20 mg/kg) or normal saline and MWA at a power of 15 W. Tumor volume was recorded. Expression of Ki67 and apoptosis-related proteins were detected by immunohistochemistry and western blotting. TUNEL assays were used to detect cell death ratio. Histopathological changes were examined by hematoxylin and eosin staining. The mechanisms associated with the function of MWA combined with TGF-β1 inhibitor in HCC development were explored by western blotting. Results Combination of MWA and SB-525334 decreased the survival rate and promoted the apoptosis of HCC cells compared with MWA alone. SB-525334 enhanced the suppressive effect of MWA on tumor growth and amplified cell apoptosis. Mechanistically, MWA collaborated with SB-525334 inhibitor inactivated the TGF-β1/Smad2/Smad3 pathway. Conclusion TGF-β1 inhibitor enhances the therapeutic effect of MWA on HCC.


Mild hyperthermia with magnetic resonance- guided high intensity focused ultrasound combined with salvage chemoradiation for recurrent rectal cancer

June 2024

·

5 Reads

Introduction Pelvic recurrences from rectal cancer present a challenging clinical scenario. Hyperthermia represents an innovative treatment option in combination with concurrent chemoradiation to enhance therapeutic effect. We provide the initial results of a prospective single center feasibility study (NCT02528175) for patients undergoing rectal cancer retreatment using concurrent chemoradiation and mild hyperthermia with MR-guided high intensity focused ultrasound (MR-HIFU). Methods All patients were deemed ineligible for salvage surgery and were evaluated in a multidisciplinary fashion with a surgical oncologist, radiation oncologist and medical oncologist. Radiation was delivered to a dose of 30.6 Gy in 1.8 Gy per fraction with concurrent capecitabine. MR-HIFU was delivered on days 1, 8 and 15 of concurrent chemoradiation. Our primary objective was feasibility and toxicity. Results Six patients (total 11 screened) were treated with concurrent chemoradiation and mild hyperthermia with MR-HIFU. Tumor size varied between 3.1-16.6 cm. Patients spent an average of 228 min in the MRI suite and sonication with the external transducer lasted an average of 35 min. There were no complications on the day of the MR-HIFU procedure and all acute toxicities (no grade >/=3 toxicities) resolved after completion of treatment. There were no late grade >/=3 toxicities. Conclusion Mild hyperthermia with MR-HIFU, in combination with concurrent chemoradiation for appropriately selected patients, is safe for localized pelvic recurrences from rectal cancer. The potential for MR-HIFU to be applied in the recurrent setting in rectal cancer treatment requires further technical development and prospective evaluation.


Experimental design five treatment groups were used to investigate the effects of histotripsy treatment through gas blockage. From left: Control treatments without blockage, bowel positioned 0 cm above the agar phantom at both normal and double amplitude, and bowel positioned 1 and 2 cm above the phantom. The therapeutic beam path is denoted by the dotted lines. A 2.5 cm diameter spherical treatment (red circle) was prescribed in each phantom. Following histotripsy treatment, the bowel was inspected for gross and microscopic signs of damage.
Experimental setup. A) the treatment head (pink arrow) of a clinical-grade histotripsy system was positioned in a degassed water bath above an agar phantom (white arrows) with gas-filled small bowel (yellow arrows) partially blocking the therapeutic beam path. B) Bowel was positioned 0 cm above the phantom (white arrow), shown in the sagittal plane. C) An image from the co-axially mounted diagnostic ultrasound transducer shows the bowel (yellow arrow) positioned above the phantom (white arrow) in the axial plane, which has been obscured by the intraluminal gas.
Treated Phantoms. Phantoms (4.6 cm × 4.6 cm × 4.6 cm) were sliced twice following treatment to facilitate measurements in both the axial and sagittal planes. A) The AP and TRANS diameters were visible following a slice in the axial plane, illustrated by the drawing on the right. B) The AP and CC diameters in the same phantom were visible in the sagittal plane.
Computer simulation a ray-tracing approach was used to estimate the amount of the therapeutic transducer face (blue) blocked by gas-filled bowel (green) that extends in the CC direction. Yellow rays represent unobstructed therapeutic ultrasound that reaches the target while red rays represent blocked ultrasound intersecting with gas-filled bowel.
Gross and microscopic pathology. A) bivalved small bowel sectioned longitudinally. There were no signs of visible damage to the small bowel mucosa following treatment. B) Treated tissue taken from the center point of the gross sample shows intact mucosa, lamina propria, submucosa, and muscularis propria (20× magnification, H&E). C) untreated control tissue harvested from bowel outside of the ultrasound beam demonstrates no signs of damage (20× magnification, H&E).
Safety and efficacy of histotripsy delivery through overlying gas-filled small bowel in an ex vivo swine model

June 2024

·

11 Reads

Purpose To evaluate the safety and efficacy of performing histotripsy through overlying gas-filled bowel in an ex vivo swine model. Methods An ex vivo model was created to simulate histotripsy treatment of solid organs through gas-filled bowel. Spherical 2.5 cm histotripsy treatments were performed in agar phantoms for each of five treatment groups: 1) control with no overlying bowel (n = 6), 2) bowel 0 cm above phantom (n = 6), 3) bowel 1 cm above phantom (n = 6), 4) bowel 2 cm above phantom (n = 6), and 5) bowel 0 cm above the phantom with increased treatment amplitude (n = 6). Bowel was inspected for gross and microscopic damage, and treatment zones were measured. A ray-tracing simulation estimated the percentage of therapeutic beam path blockage by bowel in each scenario. Results All histotripsy treatments through partial blockage were successful (24/24). No visible or microscopic damage was observed to intervening bowel. Partial blockage resulted in a small increase in treatment volume compared to controls (p = 0.002 and p = 0.036 for groups with bowel 0 cm above the phantom, p > 0.3 for bowel 1 cm and 2 cm above the phantom). Gas-filled bowel was estimated to have blocked 49.6%, 35.0%, and 27.3% of the therapeutic beam at 0, 1, and 2 cm, respectively. Conclusion Histotripsy has the potential to be applied through partial gas blockage of the therapeutic beam path, as shown by this ex vivo small bowel model. Further work in an in vivo survival model appears indicated.


Risk factors affecting long-term efficacy of ultrasound-guided high-intensity focused ultrasound treatment for multiple uterine fibroids

June 2024

·

3 Reads

Objectives To investigate the long-term efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for multiple uterine fibroids and the factors associated with recurrence. Materials and methods Five hundred and forty-nine patients with multiple uterine fibroids treated with USgHIFU from June 2017 to June 2019 were retrospectively analyzed. The Pictorial Blood Loss Assessment Chart (PBAC) was used to assess menstrual blood loss. The patients were asked to undergo pre- and post-USgHIFU magnetic resonance imaging (MRI) and complete routine follow-up after USgHIFU. Cox regression analysis was used to investigate the risk factors associated with recurrence. Results The median number of fibroids per patient was 3 (interquartile range: 3–4), and a total of 1371 fibroids were treated. Among them, 446 patients completed 3 years follow-up. Recurrence, defined as PBAC score above or equal to 100 and/or the residual fibroid volume increased by 10%, was detected in 90 patients within 3 years after USgHIFU, with a cumulative recurrence rate of 20.2% (90/446). The multi-factor Cox analysis showed that age was a protective factor for recurrence. Younger patients have a greater chance of recurrence than older patients. Mixed hyperintensity of fibroids on T2WI and treatment intensity were risk factors for recurrence. Patients with hyperintense uterine fibroids and treated with lower treatment intensity were more likely to experience recurrence than other patients after USgHIFU. No major adverse effects occurred. Conclusions USgHIFU can be used to treat multiple uterine fibroids safely and effectively. The age, T2WI signal intensity and treatment intensity are factors related to recurrence.


Impact of surrounding tissue-type and peri-electrode gap in stereoelectroencephalography guided (SEEG) radiofrequency thermocoagulation (RF-TC): a computational study

June 2024

·

27 Reads

Purpose To use computational modeling to provide a complete and logical description of the electrical and thermal behavior during stereoelectroencephalography-guided (SEEG) radiofrequency thermo­coagulation (RF-TC). Methods A coupled electrical-thermal model was used to obtain the temperature distributions in the tissue during RF-TC. The computer model was first validated by an ex vivo model based on liver fragments and later used to study the impact of three different factors on the coagulation zone size: 1) the difference in the tissue surrounding the electrode (gray/white matter), 2) the presence of a peri-electrode gap occupied by cerebrospinal fluid (CSF), and 3) the energy setting used (power-duration). Results The model built for the experimental validation was able to predict both the evolution of impedance and the short diameter of the coagulation zone (error < 0.01 mm) reasonably well but overestimated the long diameter by 2 − 3 mm. After adapting the model to clinical conditions, the simulation showed that: 1) Impedance roll-off limited the coagulation size but involved overheating (around 100 °C); 2) The type of tissue around the contacts (gray vs. white matter) had a moderate impact on the coagulation size (maximum difference 0.84 mm), and 3) the peri-electrode gap considerably altered the temperature distributions, avoided overheating, although the diameter of the coagulation zone was not very different from the no-gap case (<0.2 mm). Conclusions This study showed that computer modeling, especially subject- and scenario-specific modeling, can be used to estimate in advance the electrical and thermal performance of the RF-TC in brain tissue.


Pelvic magnetic resonance image of a type II–Ⅵ uterine fibroids. (A) Sagittal view of the T2-weighted image reveals the fibroid located in the posterior wall and fundus of the uterus, extending more than 50% into the muscular layer. (B) Transverse images demonstrate the fibroid on the posterior wall protruding into the uterine cavity, with an anteroposterior diameter of 8 cm.
Hysteroscopic image of a single type II–Ⅵ fibroid before and after HIFU. (A) Preoperative hysteroscopy shows that 20% of the fibroid protrudes into the uterine cavity. (B) On the second day after HIFU, hysteroscopy reveals that 60% of the fibroid now protrudes into the uterine cavity.
Contrast-enhanced ultrasound image obtained from a patient with a solitary type II–Ⅵ fibroid. (A) Pre-HIFU contrast-enhanced ultrasound showed significant perfusion of the fibroid. (B) Post-HIFU contrast-enhanced ultrasound showed no perfusion of the fibroids. The fibroid was completely ablated.
Feasibility, safety and efficacy of high intensity focused ultrasound ablation as a preoperative treatment for challenging hysteroscopic myomectomy

Purpose To investigate the feasibility, safety and efficacy of high intensity focused ultrasound ablation (HIFU) as a preoperative treatment for challenging hysteroscopic myomectomies. Materials and methods A total of 75 patients diagnosed with types 0–III of uterine fibroids were enrolled. Based on the Size, Topography, Extension of the base, Penetration and lateral Wall position (STEPW) classification scoring system, 25 cases with a score ≥ 5 points were treated with HIFU followed by hysteroscopic myomectomy (HIFU + HM group), whereas 50 cases with a score < 5 points were treated with hysteroscopic myomectomy (HM group). Results The median preoperative STEPW score was 7 in the HIFU + HM group and 2 in the HM group. The average non-perfused volume (NPV) ratio achieved in fibroids after HIFU was 86.87%. Patients in the HIFU + HM group underwent hysteroscopic myomectomy one to four days after HIFU, and downgrading was observed in 81.81% of fibroids. The operation time for patients in the HIFU + HM group was 73 min and the success rate of myomectomy in a single attempt was 60%. The volume of distention medium used during the operation was greater in the HIFU + HM group than in the HM group (15,500 ml vs. 7500 ml). No significant difference was observed between the two groups in terms of intraoperative blood loss, the incidence of intraoperative and postoperative complications, menstrual volume score, or uterine fibroid quality of life score. Conclusion HIFU can be utilized as a preoperative treatment for large submucosal fibroids prior to hysteroscopic myomectomy. HIFU offers a novel approach in the management of this subset of patients.


Changes in clinical signs before and after treatment. (a) Before treatment (the green arrow indicated the lesion’s location), (b) after 1 month of treatment, and (c) after 6 months of treatment, the lesions disappeared and the skin color basically returned to normal.
Pathological biopsies before and after treatment. (a) Before treatment, epithelial thickening, with atypical cells, indicating low-grade squamous intraepithelial lesions (hematoxylin and eosin stain, original magnification ×100), (b) after treatment, reduced epithelial thickening compared to pretreatment, without atypical cells (hematoxylin and eosin stain, original magnification ×100).
Side effects after FUS treatment and recovery from symptomatic treatment. (a) Ulcers appeared on the vulva after treatment, and the skin around the ulcers had become visibly red (yellow circle), (b) ulcers disappeared without scarring after one month of treatment (yellow circle).
Feasibility study of focused ultrasound in the treatment of vulvar low-grade squamous intraepithelial lesions with persistent symptoms

June 2024

·

2 Reads

Objective This study aimed to investigate the feasibility, efficacy, and safety of focused ultrasound (FUS) for the treatment of vulvar low-grade squamous intraepithelial lesions (VLSIL) with persistent symptoms. Methods This retrospective analysis included 24 VLSIL patients who underwent FUS treatment. At each follow-up visit, the clinical response was assessed including changes in symptoms and signs. In addition, the histological response was assessed based on the vulvar biopsy results of the 3rd follow-up. Clinical and histological response were assessed to elucidate the efficacy. Results A total of 22 patients completed follow-up and post-treatment pathological biopsies. After treatment, the clinical scores of itching decreased from 2.55 ± 0.51 to 0.77 ± 0.81 (p < 0.05). Furthermore, the clinical response rate and histological response rate were 86.4% and 81.8%, respectively. Only two cured patients indicated recurrence in the 3rd and 4th year during the follow-up period and achieved cure after re-treatment. In terms of adverse effects, only one patient developed ulcers after treatment, which healed after symptomatic anti-inflammatory treatment without scarring, and no other treatment complications were found in any patients. None of the patients developed a malignant transformation during the follow-up period. Conclusion This study revealed that FUS is feasible, effective, and safe for treating VLSIL patients with persistent symptoms, providing a new solution for the noninvasive treatment of symptomatic VLSIL.


Microwave ablation and saline perfusion of the tumor cavity. (a) An MWA antenna was then placed successively in the upper and lower midpoint of the lesion through the access cannulas. (b) After the ablation process, the membrane linings of the cyst wall were inactivated (Black). Through a syringe (Blue), the bone cyst was repeatedly perfused and flushed with normal saline, allowing the sanguineous fluid and necrotic tissue to be expelled through the other syringe (Red) until the fluid ran cool and clear.
A 9-year-old boy originally presented with right proximal humerus UBC with the symptoms of pain and pathological fracture. (a) Before treatment, an expansile lucent lesion was found in the proximal humerus in the frontal radiograph, with cortical thinning and interruption. (b) On the second day after the surgical procedure, scattered high-density shadows can be observed surrounding the lesion, indicative of the synthetic bone substitute utilized during the treatment. (c, b, and d): the radiographs were taken at 3-, 9- and 12-months postoperatively, respectively. Follow-up radiographs showed a gradual reduction in fracture lines and an increase in callus formation, indicating ongoing bone remodeling and consolidation, consistent with healing changes. The radiograph at 12 months (e) demonstrated near-complete remineralization of UBC and fracture healing and the cortical bone was thickened and remodeled.
A representative MWA and bone grafting treatment to a mid-shaft humerus UBC.
(a) A 15-year-old boy was diagnosed with a bone cyst after experiencing pain. (b) Postprocedural radiograph on the second day. (c) Postprocedural radiograph after one and a half months. (d) The postoperative humerus AP radiograph in 6 months exhibited the vast majority of UBC remineralization.
Percutaneous microwave ablation, perfusion, and reconstruction combined with a synthetic bone substitute in symptomatic bone cysts: a minimum of 26 months follow-up

June 2024

·

8 Reads

Purpose The objective was to describe the technique and clinical outcome of microwave thermal ablation (MWA) and perfusion combined with synthetic bone substitutes in treating unicameral bone cysts (UBCs) in adolescents. Materials and Methods A total of 14 consecutive patients were enrolled by percutaneous MWA and saline irrigation combined with synthetic bone substitutes. Clinical follow-up included the assessment of pain, swelling, and functional mobility. Radiological parameters included tumor volume, physis-cyst distance, cortical thickness of the thinnest cortical bone, and the Modified Neer classification system. Results The mean follow-up was 28.9 months (26–52 months). All UBCs were primary, and all patients underwent the MWA, saline perfusion, and reconstruction combined with a synthetic bone substitute session, except for one patient (7.1%) who required a second session. All patients had good clinical results at the final follow-up. Satisfactory cyst healing was achieved in 13 cases according to radiological parameters. Tumor volume decreased from a mean of 49.7 cm³ before surgery treatment to 13.9 cm³ at the final follow-up (p < 0.01). The physis-cyst distance increased from a mean of 3.17–4.83 cm at the final follow-up (p < 0.01). Cortical thickness improved from a mean of 1.1 mm to 2.0 mm at the final follow-up (p < 0.01). According to the proposed radiological criteria, our results were considered successful (Grading I and II) in 13 patients (92.9%) at the final follow-up. Conclusion Percutaneous microwave ablation combined with a bone graft substitute is a minimally invasive, effective, safe, and cost-effective approach to treating primary bone cysts in the limbs of adolescents.


Change in tumor volume percentage before RFA and RT and at each follow-up.
Error bars represent the standard error of the mean; ***p ≤ 0.001
A 63-year-old man with recurrent thyroid cancer.
(a) contrast-enhanced CT before RFA and RT, showing one enhanced mass invading the tracheal wall and esophageal wall; (b) PET-CT before RFA and RT, showing increased FDG uptake in the paratracheal mass lesion (SUV max: 22.25); (c) contrast-enhanced CT 39 months after RFA and RT, showing that the recurrent tumor had almost completely disappeared; (d) PET-CT 6 months after RFA and RT, showing background FDG avidity with complete metabolic response in the left paratracheal region; CT, computed tomography; RFA, radiofrequency ablation; RT, radiotherapy; PET-CT, positron emission tomography and computed tomography; FDG: fludeoxyglucose F-18; SUV max, maximum standardized uptake value
The relationship between relative tumor volume and relative Tg in patients with localized recurrent disease and initial detectable Tg (Pearson correlation coefficient, 0.886; p < 0.001).
(A) OS and (B) locoregional PFS of eligible patients after salvage RFA and RT.
Salvage radiofrequency ablation followed by external beam radiotherapy for inoperable recurrent differentiated thyroid cancer

Purpose The treatment of recurrent thyroid cancer with critical organ invasion is challenging. The combination of radiofrequency ablation (RFA) and external beam radiation therapy (EBRT) has been proposed as an effective option. This study evaluates outcomes for inoperable residual/recurrent differentiated thyroid cancer (rDTC) patients treated with RFA followed by EBRT. Materials and Methods Patients with rDTC treated with RFA followed by EBRT were retrospectively studied. RFA was performed using a free‐hand, ‘moving‐shot’ technique under US or CT guidance. For lesions invading critical structures intolerant to ‘en bloc’ high-temperature RFA, limited-field EBRT using 6‐ or 10‐MV photons was used for adjuvant treatment at a dose of 66 Gy in 33 daily fractions. Toxicities and outcomes were reviewed. Results Between April 2020 and January 2022, 11 patients with 14 rDTC lesions underwent RFA followed by EBRT. Five patients had metastatic lesions at rDTC diagnosis. With a median follow-up period of 33.7 months, all patients maintained locoregional control, while achieving a 2-year survival rate of 90.9%. This combined treatment achieved a volume reduction ratio of 92.1% ± 5.1%. The mean nadir thyroglobulin level in patients without initial distant metastases after treatment was 1.40 ± 0.81 ng/ml. Regarding treatment-related complications, one patient (9%) experienced temporary hoarseness after RFA, grade 2 radiation dermatitis occurred in 3 patients (27.2%), and grade 2 dysphagia was noted in 4 patients (36.4%). No grade 3 or greater toxicities occurred. Conclusions Salvage RFA followed by EBRT is feasible, effective and safe for patients with rDTC.


High PIV was associated with unfavorable recurrence-free survival (RFS) and overall survival (OS) in early-stage hepatocellular carcinoma treated by curative RFA in testing cohort B after propensity score matching. Kaplan-Meier curves for RFS (A) and OS (B) of patients with high or low PIV. PIV: pan-immune-inflammation value; RFA: radiofrequency ablation.
Prognostic role of PIV was validated in external validating cohort C after propensity score matching. The time-dependent receiver operating characteristic curve (A) of PIV cutoff derived from training cohort A to predict the 5-year overall survival (OS), and Kaplan-Meier curves for OS (B) and recurrence-free survival (C) in early-stage hepatocellular carcinoma treated by curative RFA in external validating cohort C. AUC: area under curve; PIV: pan-immune-inflammation value; RFA: radiofrequency ablation.
The PIV-based nomogram (A) and calibration curves for predicting the 2-year (B) and 5-year (C) OS in external validating cohort C after propensity score matching. PIV: pan-immune-inflammation value; OS: overall survival; BCLC: Barcelona clinic liver cancer.
The PIV-based nomogram (A) and calibration curves for predicting the 2-year (B) and 5-year (C) RFS in external validating cohort C after propensity score matching. PIV: pan-immune-inflammation value; RFS: recurrence-free survival; BCLC: Barcelona clinic liver cancer.
Adjuvant AA-ICI treatment following curative RFA exhibited more benefit in early-stage hepatocellular carcinoma patients in high-risk group in the pooled cohort D. Kaplan-Meier curves for RFS (A) and OS (B) of patients in low-risk group with adjuvant AA-ICI treatment or not. Kaplan-Meier curves for RFS (C) and OS (D) of patients in high-risk group with adjuvant AA-ICI treatment or not. RFA: radiofrequency ablation; RFS: recurrence-free survival; OS: overall survival; AA-ICI: anti-angiogenesis target therapy plus immune checkpoint inhibitor.
Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment

Background This study aimed to explore the prognostic role of pan-immune-inflammation value (PIV) and develop a new risk model to guide individualized adjuvant systemic treatment following radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC). Materials and methods Patients with early-stage HCC treated by RFA were randomly divided into training cohort A (n = 65) and testing cohort B (n = 68). Another 265 counterparts were enrolled into external validating cohort C. Various immune-inflammatory biomarkers (IIBs) were screened in cohort A. Prognostic role of PIV was evaluated and validated in cohort B and C, respectively. A nomogram risk model was built in cohort C and validated in pooled cohort D. Clinical benefits of adjuvant anti-angiogenesis therapy plus immune checkpoint inhibitor (AA-ICI) following RFA was assessed in low- and high-risk groups. Results The cutoff point of PIV was 120. High PIV was an independent predictor of unfavorable recurrence-free survival (RFS) and overall survival (OS). RFS and OS rates of patients with high PIV were significantly lower than those with low PIV both in cohort B (PRFS=0.016, POS=0.011) and C (PRFS<0.001, POS<0.001). The nomogram model based on PIV, tumor number and BCLC staging performed well in risk stratification in external validating cohort C. Adjuvant AA-ICI treatment showed an added benefit in OS (p = 0.011) for high-risk patients. Conclusions PIV is a feasible independent prognostic factor for RFS and OS in early-stage HCC patients who received curative RFA. The proposed PIV-based nomogram risk model could help clinicians identify high-risk patients and tailor adjuvant systemic treatment and disease follow-up scheme.


ROC curves for prediction of local tumor progression according to clinical model (green), pure radiomic model (red), and combined model (blue) on T1-HBP images (figure a) and T2 images (figure b), respectively.
Kaplan Meyer curve for low-risk (green) and high risk group (red) as identified by the clinical model on local tumor progression.
Kaplan Meyer curve for low-risk (green) and high risk group (red) as identified by the T1-HBP-based (figure a) and T2-based (figure b) radiomic model on local tumor progression.
Kaplan Meyer curve for low-risk (green) and high risk group (red) as identified by the T1-HBP-based (figure a) and T2-based (figure b) combined model on local tumor progression.
Preoperative MRI radiomic analysis for predicting local tumor progression in colorectal liver metastases before microwave ablation

May 2024

·

12 Reads

Purpose Radiomics may aid in predicting prognosis in patients with colorectal liver metastases (CLM). Consistent data is available on CT, yet limited data is available on MRI. This study assesses the capability of MRI-derived radiomic features (RFs) to predict local tumor progression-free survival (LTPFS) in patients with CLMs treated with microwave ablation (MWA). Methods All CLM patients with pre-operative Gadoxetic acid-MRI treated with MWA in a single institution between September 2015 and February 2022 were evaluated. Pre-procedural information was retrieved retrospectively. Two observers manually segmented CLMs on T2 and T1-Hepatobiliary phase (T1-HBP) scans. After inter-observer variability testing, 148/182 RFs showed robustness on T1-HBP, and 141/182 on T2 (ICC > 0.7). Cox multivariate analysis was run to establish clinical (CLIN-mod), radiomic (RAD-T1, RAD-T2), and combined (COMB-T1, COMB-T2) models for LTPFS prediction. Results Seventy-six CLMs (43 patients) were assessed. Median follow-up was 14 months. LTP occurred in 19 lesions (25%). CLIN-mod was composed of minimal ablation margins (MAMs), intra-segment progression and primary tumor grade and exhibited moderately high discriminatory power in predicting LTPFS (AUC = 0.89, p = 0.0001). Both RAD-T1 and RAD-T2 were able to predict LTPFS: (RAD-T1: AUC = 0.83, p = 0.0003; RAD-T2: AUC = 0.79, p = 0.001). Combined models yielded the strongest performance (COMB-T1: AUC = 0.98, p = 0.0001; COMB-T2: AUC = 0.95, p = 0.0003). Both combined models included MAMs and tumor regression grade; COMB-T1 also featured 10th percentile of signal intensity, while tumor flatness was present in COMB-T2. Conclusion MRI-based radiomic evaluation of CLMs is feasible and potentially useful for LTP prediction. Combined models outperformed clinical or radiomic models alone for LTPFS prediction.


Cell survival after hyperthermia of endothelial cells, smooth muscle cells, keratinocytes, and neuronal cells. Fits for survival data is also shown through the line plots. Survival fractions are relative to the ATP levels at exposure to 37 °C. Dots indicates the median of the cell data (n = 9), with error bars indicating the full range. Line plots indicate the Arrhenius damage model for thermal damage, error bands show the 95% CI. bars indicate the standard deviation of the median.
Temperature and time combinations that result in reduction of cell viability by 50% (LT50) of the linear interpolated points (symbols, n = 9, median with 95%CI) and the fitted LT50s using the Arrhenius model (lines, median, 95% CI, n = 5000). Significance levels of differences between the cell types are indicated with * for p < 0.0001 at α = 0.05.
Illustration of heat diffusion of pulsed dye laser light from the blood vessels where the chromophore oxyhemoglobin resides toward the surrounding areas. These could include the (peri)vascular nerves, free nerve fiber endings, and keratinocytes.
Subminute thermal damage to cell types present in the skin

May 2024

·

10 Reads

Introduction Psoriasis is characterized by an increase in the proliferation of keratinocytes and nerve fiber activity, contributing to the typical skin lesions. Pulsed Dye Laser (PDL) treatment is effective for the treatment of psoriatic lesions but its mechanism remains unclear. One hypothesis is that PDL causes thermal damage by the diffusion of heat to neighboring structures in lesional skin. There is limited information on the thermal sensitivity of these neighboring skin cells when exposed to hyperthermia for durations lasting less than a minute. Our study aimed to investigate the cell-specific responses to heat using sub-minute exposure times and moderate to ablative hyperthermia. Materials and Methods Cultured human endothelial cells, smooth muscle cells, neuronal cells, and keratinocytes were exposed to various time (2–20 sec) and temperature (45–70 °C) combinations. Cell viability was assessed by measuring intracellular ATP content 24 h after thermal exposure and this data was used to calculate fit parameters for the Arrhenius model and CEM43 calculations. Results Our results show significant differences in cell survival between cell types (p < 0.0001). Especially within the range of 50–60 °C, survival of neuronal cells and keratinocytes was significantly less than that of endothelial and smooth muscle cells. No statistically significant difference was found in the lethal dose (LT50) of thermal energy between neuronal cells and keratinocytes. However, CEM43 calculations showed significant differences between all four cell types. Conclusion The results imply that there is a cell-type-dependent sensitivity to thermal damage which suggests that neuronal cells and keratinocytes are particularly susceptible to diffusing heat from laser treatment. Damage to these cells may aid in modulating the neuro-inflammatory pathways in psoriasis. These data provide insight into the potential mechanisms of PDL therapy for psoriasis and advance our understanding of how thermal effects may play a role in its effectiveness.


Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells

Objective Incomplete thermal ablation (ITA) fosters the malignancy of residual cells in Hepatocellular carcinoma (HCC) with unclear mechanisms now. This study aims to investigate the expression changes of NDST2 following ITA of HCC and its impact on residual cancer cells. Methods An in vitro model of heat stress-induced liver cancer was constructed to measure the expression of NDST2 using Quantitative Real-Time PCR and Western blotting experiments. The sequencing data from nude mice were used for validation. The clinical significance of NDST2 in HCC was evaluated by integrating datasets. Gene ontology and pathway analysis were conducted to explore the potential signaling pathways regulated by NDST2. Additionally, NDST2 was knocked down in heat stress-induced HCC cells, and the effects of NDST2 on these cells were verified using Cell Counting Kit-8 assays, scratch assays, and Transwell assays. Results NDST2 expression levels are elevated in HCC, leading to a decrease in overall survival rates of HCC patients. Upregulation of immune checkpoint levels in high NDST2-expressing HCC may contribute to immune evasion by liver cancer cells. Additionally, the low mutation rate of NDST2 in HCC suggests a relatively stable expression of NDST2 in this disease. Importantly, animal and cell models treated with ITA demonstrate upregulated expression of NDST2. Knockdown of NDST2 in heat stress-induced liver cancer cells results in growth inhibition associated with gene downregulation. Conclusion The upregulation of NDST2 can accelerate the progression of residual HCC after ITA, suggesting a potential role for NDST2 in the therapeutic efficacy and prognosis of residual HCC.


Participant flow through study.
Feasibility and acceptability of an integrated mind-body intervention for depression: whole-body hyperthermia (WBH) and cognitive behavioral therapy (CBT)

May 2024

·

29 Reads

Background: There is a pressing need for effective treatments for major depressive disorder (MDD). Objective To examine the feasibility of an integrated mind-body MDD treatment combining cognitive behavioral therapy (CBT) and whole-body hyperthermia (WBH). Methods In this single-arm trial, 16 adults with MDD initially received 8 weekly CBT sessions and 8 weekly WBH sessions. Outcomes included WBH sessions completed (primary), self-report depression assessments completed (secondary), and pre-post intervention changes in depression symptoms (secondary). We also explored changes in mood and cognitive processes and assessed changes in mood as predictors of overall treatment response. Results Thirteen participants (81.3%) completed ≥ 4 WBH sessions (primary outcome); midway through the trial, we reduced from 8 weekly to 4 bi-weekly WBH sessions to increase feasibility. The n = 12 participants who attended the final assessment visit completed 100% of administered self-report depression assessments; all enrolled participants (n = 16) completed 89% of these assessments. Among the n = 12 who attended the final assessment visit, the average pre-post-intervention BDI-II reduction was 15.8 points (95% CI: −22.0, −9.70), p = 0.0001, with 11 no longer meeting MDD criteria (secondary outcomes). Pre-post intervention improvements in negative automatic thinking, but not cognitive flexibility, achieved statistical significance. Improved mood from pre-post the initial WBH session predicted pre-post treatment BDI-II change (36.2%; rho = 0.60, p = 0.038); mood changes pre-post the first CBT session did not. Limitations Small sample size and single-arm design limit generalizability. Conclusion An integrated mind-body intervention comprising weekly CBT sessions and bi-weekly WBH sessions was feasible. Results warrant future larger controlled clinical trials. Clinivaltrials.gov Registration: NCT05708976


Endoscopic images of patients with VaIN I before and after treatment are shown in Figure 1. (a) Represents the appearance of the lesion site before treatment when 3% glacial acetic acid was applied. (b) Shows the lesion site before treatment when Lugol’s iodine solution was applied for recurrent staining. (c) Displays the lesion site after 6 months reexamination following treatment when 3% glacial acetic acid was applied. Finally, (d) demonstrates the lesion site after half a year’s reexamination following treatment when Lugol’s iodine solution was applied. The blue arrow indicates the location of the lesion in the images.
Endoscopic images of patients with vaginal stump VaIN I before and after treatment are presented in Figure 2. (a) Shows the appearance of the lesion site before treatment when 3% glacial acetic acid was applied. (b) Displays the lesion site before treatment when Lugol’s iodine solution was applied for recurrent staining. After half a year’s reexamination following treatment, (c) exhibits the lesion site when 3% glacial acetic acid was applied. Finally, (d) demonstrates the lesion site after half a year’s reexamination following treatment when Lugol’s iodine solution was applied. The blue arrow indicates the location of the lesion in the images.
Study on the safety and efficacy of HIFU in the treatment of VaIN

May 2024

·

18 Reads

Purpose This study aimed to investigate the safety and efficacy of High-Intensity Focused Ultrasound (HIFU) treatment for vaginal intraepithelial neoplasia(VaIN). Methods Retrospective analysis was conducted on clinical, pathological, and follow-up data of 43 patients who underwent HIFU treatment for VaIN at Xiangya Third Hospital of Central South University between January 2018 and December 2022. The preliminary efficacy and safety of HIFU in treating VaIN were discussed. Results The 36 patients were analyzed, and the average age was 50.09 ± 12.06 years, including 24 patients with VaIN I and 12 patients with VaIN II. Five cases had a history of hysterectomy (4 due to cervical lesions, 1 due to hysteromyoma), and 2 cases had conization of cervical intraepithelial lesions (CIN). All 36 cases were complicated by human papillomavirus (HPV) infection, with 3 cases also having grade I-II CIN and undergoing cervical HIFU treatment. All patients successfully completed the HIFU treatment, with an average treatment time of 5.99 ± 1.25 min, treatment power of 3.5 W, and average total treatment dose of 1118.99 ± 316.20 J. Patients tolerated the treatment well, experiencing only slight pain with VAS score of 3. There was a mild postoperative burning sensation, which resolved within approximately 10-20 min. After 6 follow-up visits, 33 patients (91.66%) achieved cure, 1 patient (2.77%) showed persistence, 2 patients (5.55%) exhibited progression, and 27 patients (75%) tested negative for HPV. At 12 months of follow-up, the results were consistent with those of 6 months. No complications occurred during the procedure and the follow-up period. Conclusion HIFU is a safe and effective treatment for VaIN. However, this study had a small sample size, a relatively short follow-up period, and lacked a control group, requiring further investigation.


Photographs of goniometry measurement of the ankle range of motion with the knee stabilized in (a) full extension of 0°, (b) flexion of 90°, and (c) flexion of 135° flexion, while the angle of the ankle at maximal dorsiflexion was measured.
T2-weighted MRI image of the Achilles tendon used in treatment planning of MRgFUS sonication. Treatment target is verified in the (a) sagittal, (b) axial, and (c) coronal views.
T2-weighted MRI image of the Achilles tendon with MR thermometry (PRFS-MRT) at the end of the MRgFUS thermal ablation sonication showing the maximum temperature achieved for Group 2B (pulsed FUS and 900 J). Temperature mapping corresponds to the scale (blue = 40°, yellow = 55°, red = 70°) displayed on the right for PRFS-MRT in (a) sagittal, (b) axial, and (c) coronal views. The white lines represent the sonication cone; the yellow lines represent the treatable sonication region.
MRI image of the Achilles tendon with MR thermometry (PRFS-MRT) at the end of MRgFUS sonication showing the maximum temperature achieved for Group 2 A (900 J only). Temperature mapping corresponds to the scale displayed on the right for PRFS-MRT in (a) sagittal, (b) axial, and (c) coronal views. The white lines represent the sonication cone; the yellow lines represent the treatable sonication region.
Noninvasive release of tendons using MRI guided focused ultrasound: a hybrid therapy using long-pulse focused ultrasound followed by thermal ablation

May 2024

·

15 Reads

Introduction Magnetic Resonance-guided Focused Ultrasound (MRgFUS) thermal ablation is an effective noninvasive ultrasonic therapy to disrupt in vivo porcine tendon but is prone to inducing skin burns. We evaluated the safety profile of a novel hybrid protocol that minimizes thermal spread by combining long-pulse focused ultrasound followed by thermal ablation. Methods In-vivo Achilles tendons (hybrid N = 15, thermal ablation alone N = 21) from 15 to 20 kg Yorkshire pigs were randomly assigned to 6 treatment groups in two studies. The first (N = 21) was ablation (600, 900, or 1200 J). The second (N = 15) was hybrid: pulsed FUS (13.5 MPa peak negative pressure) followed by ablation (600, 900, or 1200 J). Measurements of ankle range of motion, tendon temperature, thermal dose (240 CEM43), and assessment of skin burn were performed in both groups. Results Rupture was comparable between the two protocols: 1/5 (20%), 5/5 (100%) and 5/5 (100%) for hybrid protocol, compared to 2/7 (29%), 6/7 (86%) and 7/7 (100%) for the ablation-only protocol with energies of 600, 900, and 1200 J, respectively. The hybrid protocol produced lower maximum temperatures, smaller areas of thermal dose, fewer thermal injuries to the skin, and fewer full-thickness skin burns. The standard deviation for the area of thermal injury was also smaller for the hybrid protocol, suggesting greater predictability. Conclusion This study demonstrated a hybrid MRgFUS protocol combining long-pulse FUS followed by thermal ablation to be noninferior and safer than an ablation-only protocol for extracorporeal in-vivo tendon rupture for future clinical application for noninvasive release of contracted tendon.


Volumetric hyperthermia delivery using the ExAblate Body MR-guided focused ultrasound system

May 2024

·

19 Reads

Objectives To investigate image-guided volumetric hyperthermia strategies using the ExAblate Body MR-guided focused ultrasound ablation system, involving mechanical transducer movement and sector-vortex beamforming. Materials and methods Acoustic and thermal simulations were performed to investigate volumetric hyperthermia using mechanical transducer movement combined with sector-vortex beamforming, specifically for the ExAblate Body transducer. The system control in the ExAblate Body system was modified to achieve fast transducer movement and MR thermometry-based hyperthermia control, mechanical transducer movements and electronic sector-vortex beamforming were combined to optimize hyperthermia delivery. The experimental validation was performed using a tissue-mimicking phantom. Results The developed simulation framework allowed for a parametric study with varying numbers of heating spots, sonication durations, and transducer movement times to evaluate the hyperthermia characteristics for mechanical transducer movement and sector-vortex beamforming. Hyperthermic patterns involving 2-4 sequential focal spots were analyzed. To demonstrate the feasibility of volumetric hyperthermia in the system, a tissue-mimicking phantom was sonicated with two distinct spots through mechanical transducer movement and sector-vortex beamforming. During hyperthermia, the average values of Tmax, T10, Tavg, T90, and Tmin over 200 s were measured within a circular ROI with a diameter of 10 pixels. These values were found to be 8.6, 7.9, 6.6, 5.2, and 4.5 °C, respectively, compared to the baseline temperature. Conclusions This study demonstrated the volumetric hyperthermia capabilities of the ExAblate Body system. The simulation framework developed in this study allowed for the evaluation of hyperthermia characteristics that could be implemented with the ExAblate MRgFUS system.


Study design flow chart.
The comparison of the values of liver function before and after UPMWA. (*p < 0.05, as determined by a t-test comparing the values before and after UPMWA).
The comparison of the values of RBC and HGB before and after UPMWA. (*p < 0.05, as determined by a t-test comparing the values before and after UPMWA).
The comparison of the values of kidney function before and after UPMWA. (*p < 0.05, as determined by a t-test comparing the values before and after UPMWA).
Changes in liver and kidney function, red blood cell count and hemoglobin levels 1 day after ultrasound-guided percutaneous microwave ablation for uterine fibroids

April 2024

·

3 Reads

Objective To investigate the changes in liver and kidney function, red blood cell (RBC) count and hemoglobin (HGB) levels in patients undergoing ultrasound-guided percutaneous microwave ablation (UPMWA) for uterine fibroids on postoperative day 1. Methods The changes in liver and kidney function, RBC count and HGB levels in 181 patients who underwent selective UPMWA in the Second Affiliated Hospital of Shantou University Medical College, China, between August 2017 and January 2023 were retrospectively analyzed. Results All patients underwent UPMWA for uterine fibroids; 179 patients had multiple uterine fibroids and 2 patients had single uterine fibroids. The maximum fibroid diameter ranged from 18 to 140 mm, with an average of 68.3 mm. Ultrasound imaging was used to confirm that the blood flow signal within the mass had disappeared in all patients, indicating that the ablation was effective. Within 24 h, compared with before UPMWA, levels of total bilirubin, direct bilirubin, indirect bilirubin and aspartate aminotransferase had significantly increased (p < 0.01), whereas levels of total protein, albumin, globulin, alanine aminotransferase, creatinine and urea had significantly decreased (p < 0.01). Acute kidney injury (AKI) occurred in 1 of the 181 patients. The RBC count and HGB levels decreased significantly after UPMWA (p < 0.01). Conclusion Ultrasound-guided percutaneous microwave ablation for uterine fibroids can impose a higher detoxification load on the liver and cause thermal damage to and the destruction of RBCs within local circulation, potentially leading to AKI. Protein levels significantly decreased after UPMWA. Therefore, perioperative organ function protection measures and treatment should be actively integrated into clinical practice to improve prognosis and enhance recovery.


Heat shock protein-related diagnostic signature and molecular subtypes in ankylosing spondylitis: new pathogenesis insights

April 2024

·

6 Reads

Heat shock proteins (HSP) have been associated with a range of persistent inflammatory disorders; however, little research has been conducted on the involvement of HSP in the development of ankylosing spondylitis (AS). The research aims to identify a diagnostic signature based on HSP-related genes and determine the molecular subtypes of AS. We gathered the transcriptional data of patients with AS from the GSE73754 dataset and conducted a literature search for HSP-related genes (HRGs). The logistic regression model was utilized for the identification of hub HRGs associated with AS. Subsequently, these HRGs were employed in the construction of a nomogram prediction model. We employed a consensus clustering approach to identify novel molecular subgroups. Subsequently, we conducted functional analyses, encompassing GO, KEGG, and GSEA, to elucidate the underlying mechanisms between these subgroups. To assess the immunological landscape, we employed the xCell algorithm. Through logistic regression analysis, the four core HRGs (CCT2, HSPA6, DNAJB14, and DNAJC5) were confirmed as potential biomarkers for AS. Subsequent stratification revealed two distinct molecular phenotypes, designated as Cluster 1 and Cluster 2. Notably, Cluster 2 was characterized by the upregulation of pathways pertinent to immune response and inflammation. Our research suggests that the CCT2, HSPA6, DNAJB14, and DNAJC5 exhibit potential as effective blood-based diagnostic biomarkers for AS. These findings contribute to a deeper comprehension of the underlying mechanisms involved in the development of AS and offer potential targets for personalized therapeutic interventions.


Regional hyperthermia for soft tissue sarcoma – a survey on current practice, controversies and consensus among 12 European centers

April 2024

·

76 Reads

Purpose To analyze the current practice of regional hyperthermia (RHT) for soft tissue sarcoma (STS) at 12 European centers to provide an overview, find consensuses and identify controversies necessary for future guidelines and clinical trials. Methods In this cross-sectional survey study, a 27-item questionnaire assessing clinical subjects and procedural details on RHT for STS was distributed to 12 European cancer centers for RHT. Results We have identified seven controversies and five consensus points. Of 12 centers, 6 offer both, RHT with chemotherapy (CTX) or with radiotherapy (RT). Two centers only offer RHT with CTX and four centers only offer RHT with RT. All 12 centers apply RHT for localized, high-risk STS of the extremities, trunk wall and retroperitoneum. However, eight centers also use RHT in metastatic STS, five in palliative STS, eight for superficial STS and six for low-grade STS. Pretherapeutic imaging for RHT treatment planning is used by 10 centers, 9 centers set 40–43 °C as the intratumoral target temperature, and all centers use skin detectors or probes in body orifices for thermometry. Discussion There is disagreement regarding the integration of RHT in contemporary interdisciplinary care of STS patients. Many clinical controversies exist that require a standardized consensus guideline and innovative study ideas. At the same time, our data has shown that existing guidelines and decades of experience with the technique of RHT have mostly standardized procedural aspects. Conclusions The provided results may serve as a basis for future guidelines and inform future clinical trials for RHT in STS patients.


Hyperthermia synergized with chemotherapy in promoting caspase-8 accumulation in cancer cells. (A) HepG2 cells were heated at 43 °C in water-bath for indicated times in the absence or presence of CDDP. (B) HepG2 cells were heated at indicated temperatures for 1 h. (C) HepG2 cells were treated with CDDP at different concentrations in combination with hyperthermia at 42.5 °C. (D) HepG2 cells were heated at 42.5 °C for 1 h, then cultured for various times. The densitometry ratio of Western blots of caspase-8 to GAPDH was quantified (bottom panels). Data are expressed as mean ± standard deviation (SD), three independent experiments. * p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 by t-test. Ns: not significant, compared to control.
Combination therapy promoted apoptosis of cancer cells in correlation with caspase-8 activation. (A) HepG2 cells were heated at 42.5 °C for 1h in the presence of CDDP (15 µg/mL). Cells were harvested 16 h later and cell lysates were used for assay of enzymatic activities of caspase-8 and caspase-3. (B and C) Analysis of caspase-8 and caspase-3 activation (B) and enzymatic activities (C) in the presence of pan-caspase inhibitor. (D) Cells were treated as in (A), stained with Annexin V-FITC and PI, and analyzed by flow cytometry. (E) Quantification of apoptosis in (D). (F) Cells were treated as in (A), cell viability was measured by CCK-8 assay. Data are expressed as mean ± standard deviation (SD), three independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001 by t-test.
Knockout of caspase-8 decreased the sensitivity of cancer cells to combination therapy. (A) Caspase-8 gene was edited by CRISPR/Cas9 in HepG2 cells. Targeted PCR of genomic DNA of two cloned caspase-8 knockout cells (Cas9-C8) showed deletion of a segment of caspase-8 gene. (B) Western blotting analysis of caspase-8 protein expression in the two cloned Cas9-C8 cells in (A). (C) WT and Cas9-C8 cells were treated with CDDP (15 µg/mL) and heated at 42.5 °C for 1 h. Cell viability was measured by CCK-8 assay. (D) Cells were treated as in (C) and clone formation assay was performed. Cells were fixed and stained with crystal violet and clone formation rate was calculated (right panel). Data are expressed as mean ± standard deviation (SD), three independent experiments. * p < 0.05, ****p < 0.0001 by t-test.
Combination therapy increased K63-linked polyubiquitination of caspase-8 and enhanced its interaction with p62. (A) HepG2 cells were treated with combination therapy for 1 h and cultured for another 3 h. Cell lysates were used for immunoprecipitation with antibodies specific to caspase-8 and immunoblotting were performed to analyze ubiquitination. (B) Cells were treated as in (A) in the presence of 5 µM MG132 for 4 h. (C and D) Cells were transfected with siRNAs targeting CUL3 (50 nM) for 48 h. Cell lysates were subjected to immunoblotting (C) and immunoprecipitation (D). NTC, negative siRNA control. (E) The colocalization of p62 and caspase-8 proteins was examined by immunofluorescence staining and visualized under Confocal microscopy (DAPI, cell nuclei). Scale bar, 10 μm. (F) Cells were treated with combination therapy, and cell lysates were analyzed for CUL3 expression by western blotting. (G) Co-IP of caspase-8 by p62 in cells lysates. (H) Cells were treated as in (A) in the presence of 100 nM BafA1 for 10 h or 500 nM Rapamycin for 8 h, and then analyzed by immunoblotting to evaluated caspase-8 and autophagy proteins. Data are presentative of three independent experiments.
Hyperthermia synergized with chemotherapy to promote caspase-8 dependent pyroptosis of cancer cells. (A) HepG2 cells were treated as indicated and cell lysates were analyzed for caspases and gasdermins by Western blotting with indicated antibodies. (B) HepG2 cells were pretreated with 40 µM pan-caspase inhibitor zVAD-fmk for 2 h and then treated with various therapies. Caspases and gasdermins were analyzed by Western blotting with antibodies as indicated. (C) WT and Caspase-8 knockout HepG2 cells were treated with various therapies and assessed as in (B). (D) HepG2 cells were treated with various therapies and pyroptosis was examined by scanning electron microscopy (SEM). Arrows indicate pores on cell membranes. Scale bar, 20 μm. (E) mRNA expression of inflammatory cytokines IL-1β, IL-18 and TNFα in HepG2 cells and RAW264.7 cells. (F) Measurement of LDH release in WT and Caspase-8 knockout HepG2 cells, and RAW264.7 cells. Data are expressed as mean ± standard deviation (SD), three independent experiments. * p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 compared to control; t-test.
Hyperthermia and cisplatin combination therapy promotes caspase-8 accumulation and activation to enhance apoptosis and pyroptosis in cancer cells

April 2024

·

21 Reads

Background Hyperthermia can play a synergistic role with chemotherapy in combination therapy. Although the association between caspase activation, apoptosis, and pyroptosis have been published for both cisplatin (CDDP) and hyperthermia therapies independently, the interactions between these molecular pathways in combination therapy are unknown. The present study aimed to investigate the possible interactions between caspase 8 activation, apoptosis, and pyroptosis in combination therapy. Methods Cells were treated with CDDP (15 µg/ml), followed by hyperthermia at optimized temperature (42.5 °C) in water-bath. After combination therapy, cell viability was analyzed by CCK-8, and cell death was analyzed by Annexin-V-FITC/PI and caspases activation. Immuno-staining and co-immuno-precipitation were used to examine the interaction between p62 and caspase-8. Pyroptosis was investigated by western blotting and transmission electron microscopy. E3 ligase Cullin 3 was knockdown by siRNA. In addition, caspase-8 activation was modulated by CRISPR-Cas9 gene-editing or pharmacological inhibition. Results Combination therapy promoted K63-linked polyubiquitination of caspase-8 and cellular accumulation of caspase-8. In turn, polyubiquitinated caspase-8 interacted with p62 and led to the activation of caspase-3. Knockdown of the E3 ligase Cullin 3 by siRNA reduced caspase-8 polyubiquitination and activation. In addition, combination therapy induced release of the pore-forming N-terminus from gasdermins and promoted pyroptosis along with caspase-8 accumulation and activation. Knockdown of caspase-8 by CRISPR/Cas9 based gene editing reduced the sensitivity of tumor cells to apoptosis and pyroptosis. Conclusions Our study presented a novel mechanism in which hyperthermia synergized with chemotherapy in promoting apoptosis and pyroptosis in a caspase-8 dependent manner.


Example ROI placement for intensity and CNR analysis between the IVIM-based non-perfused volume (NPV) and surrounding tissue. This example shows an f-map calculated with least-squares fitting without T2-correction.
Diffusion weighted imaging (DWI) b-value images (first two rows) and IVIM perfusion fraction maps (lower rows) of a uterine fibroid before and after MR-HIFU treatment, generated using conventional least squares (flq) and neural net (fnn) fitting techniques, and a T2-uncorrected (f) and T2-corrected (fc) IVIM model. Based on the contrast enhanced-T1w (CE-T1w) scan, the fibroid’s perfusion has been successfully eliminated in this patient. This seems to be accurately reflected on the post-HIFU perfusion fraction maps, as perfusion fraction is decreased within the fibroid in comparison to screening. The HIFU-transducer, which is located in an oil tank, is visible in the post-HIFU DWI and perfusion fraction maps and marked in the post-HIFU b0 DWI image. During treatment, the patient lies prone on a membrane on top of the transducer.
Mean perfusion fraction (f/fc) in IVIM perfusion fraction maps, between the area with low perfusion fraction in the treated fibroid and surrounding tissue, after an MR-HIFU treatment. All four types of IVIM perfusion fraction maps showed a significant difference in perfusion fraction between low-value area and surrounding tissue.
Contrast-to-noise (CNR) analysis between the low-value area in the treated fibroid and surrounding tissue in IVIM perfusion fraction (f/fc) maps. The CNR was not significantly different for any of the perfusion fraction map combinations. lq = least squares, nn = neural net, c = T2 corrected.
Bland-Altman plot of areas with low perfusion fraction (f/fc) measured on perfusion fraction maps and non-perfused areas on reference contrast enhanced T1-weighted scans, immediately after MR-HIFU treatments of uterine fibroids. lq = least squares, nn = neural net, c = T2 corrected.
Intravoxel incoherent motion (IVIM)-derived perfusion fraction mapping for the visual evaluation of MR-guided high intensity focused ultrasound (MR-HIFU) ablation of uterine fibroids

April 2024

·

16 Reads

Background A method for periprocedural contrast agent-free visualization of uterine fibroid perfusion could potentially shorten magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) treatment times and improve outcomes. Our goal was to test feasibility of perfusion fraction mapping by intravoxel incoherent motion (IVIM) modeling using diffusion-weighted MRI as method for visual evaluation of MR-HIFU treatment progression. Methods Conventional and T2-corrected IVIM-derived perfusion fraction maps were retrospectively calculated by applying two fitting methods to diffusion-weighted MRI data (b = 0, 50, 100, 200, 400, 600 and 800 s/mm² at 1.5 T) from forty-four premenopausal women who underwent MR-HIFU ablation treatment of uterine fibroids. Contrast in perfusion fraction maps between areas with low perfusion fraction and surrounding tissue in the target uterine fibroid immediately following MR-HIFU treatment was evaluated. Additionally, the Dice similarity coefficient (DSC) was calculated between delineated areas with low IVIM-derived perfusion fraction and hypoperfusion based on CE-T1w. Results Average perfusion fraction ranged between 0.068 and 0.083 in areas with low perfusion fraction based on visual assessment, and between 0.256 and 0.335 in surrounding tissues (all p < 0.001). DSCs ranged from 0.714 to 0.734 between areas with low perfusion fraction and the CE-T1w derived non-perfused areas, with excellent intraobserver reliability of the delineated areas (ICC 0.97). Conclusion The MR-HIFU treatment effect in uterine fibroids can be visualized using IVIM perfusion fraction mapping, in moderate concordance with contrast enhanced MRI. IVIM perfusion fraction mapping has therefore the potential to serve as a contrast agent-free imaging method to visualize the MR-HIFU treatment progression in uterine fibroids.


Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells

April 2024

·

38 Reads

Purpose Radiotherapy (RT) is the primary treatment for prostate cancer (PCa); however, the emergence of castration-resistant prostate cancer (CRPC) often leads to treatment failure and cancer-related deaths. In this study, we aimed to explore the use of microwave hyperthermia (MW-HT) to sensitize PCa to RT and investigate the underlying molecular mechanisms. Methods We developed a dedicated MW-HT heating setup, created an in vitro and in vivo MW-HT + RT treatment model for CRPC. We evaluated PC3 cell proliferation using CCK-8, colony experiments, DAPI staining, comet assay and ROS detection method. We also monitored nude mouse models of PCa during treatment, measured tumor weight, and calculated the tumor inhibition rate. Western blotting was used to detect DNA damage repair protein expression in PC3 cells and transplanted tumors. Results Compared to control, PC3 cell survival and clone formation rates decreased in RT + MW-HT group, demonstrating significant increase in apoptosis, ROS levels, and DNA damage. Lower tumor volumes and weights were observed in treatment groups. Ki-67 expression level was reduced in all treatment groups, with significant decrease in RT + MW-HT groups. The most significant apoptosis induction was confirmed in RT + MW-HT group by TUNEL staining. Protein expression levels of DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways significantly decreased in RT + MW-HT groups. Conclusion MW-HT + RT treatment significantly inhibited DNA damage repair by downregulating DNA-PKcs, ATM, ATR, and P53/P21 signaling pathways, leading to increased ROS levels, aggravate DNA damage, apoptosis, and necrosis in PC3 cells, a well-established model of CRPC.


Journal metrics


3.1 (2022)

Journal Impact Factor™


42%

Acceptance rate


6.2 (2022)

CiteScore™


22 days

Submission to first decision


1.070 (2022)

SNIP


0.762 (2022)

SJR

Editors